It's a single directory built to answer the questions a research or business development team needs answered before evaluating a rare disease opportunity: population and burden data, standard-of-care context, the latest published research, and a live map of a drug discovery landscape.

One page. Complete disease context.

Scattered data slows down drug discovery: prevalence figures from one registry, natural history from a review article, current treatments from a clinical guideline, competitive intensity from an orphan drug database, and the newest science from hundreds of research papers. Pulling all of that together, disease by disease, can take days, and the work has to be repeated every time the landscape evolves.

Explority AI replaces that process with a single, continuously updated page for each of 5,846 rare diseases, built on the same 1M+ paper research corpus that powers Explority's probability-of-success models, so researchers, biotech companies, and business development teams can easily:

• Spot unmet medical need

• Navigate the latest research

• Identify standard-of-care gaps

• Access ready-to-use drug discovery landscapes

Inside a disease page

Every profile follows the same structure, so learning to read one means you can read all 5,846. Take the Fabry disease page as an example.

• Overview – a clinical summary of the disease.
  
  

• Analytics – population, burden, and therapy data in three parts: how many people are affected and who they are, the clinical and economic burden of the disease, and the current standard of care.
  
  

• Research – the live count of drug discovery papers published on the disease, how many describe first-in-class or next-in-class therapies forecast to outperform average preclinical success rates, and the most recent publications, linked to the original articles.
  
  

• Drug discovery landscape – a complete table of every orphan drug designation granted for the disease by the FDA and EMA, including therapy type, regulator, designation date, approval status, and sponsor, updated as new designations are granted.

Why it's open

Explority AI's mission is to bring clarity to the earliest and riskiest stages of pharmaceutical research. Opening this directory to everyone is a first step: the more researchers, R&D teams, investors, and patient advocates who can see where the unmet need and the real opportunities lie, the faster new therapies can move from paper to patient.

Explore the full directory at explority.ai/diseases, or talk to our team about getting access to Explority AI's full probability-of-success forecasts.